What is the role of Risagiline (Rasagiline) in the treatment of Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 4, 2025 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the FDA Drug Label

The effectiveness of rasagiline for the treatment of Parkinson's disease was established in four 18- to 26-week, randomized, placebo-controlled trials, as initial monotherapy or adjunct therapy. Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson’s disease The precise mechanisms of action of rasagiline are unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum.

The role of Rasagiline in the treatment of Parkinson's disease is as a selective, irreversible MAO-B inhibitor. It is used as:

  • Monotherapy in early Parkinson’s disease patients not receiving any concomitant dopaminergic therapy
  • Adjunct therapy to dopamine agonists without levodopa Its mechanism of action is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum, mediating its beneficial effects seen in models of dopaminergic motor dysfunction 1.

From the Research

Rasagiline is a highly effective medication for treating Parkinson's disease, and it should be considered as a first-line treatment option due to its ability to improve motor symptoms and quality of life, as evidenced by the most recent and highest quality study 2.

Key Points

  • Rasagiline is a selective, irreversible monoamine oxidase-B (MAO-B) inhibitor that helps increase dopamine levels in the brain.
  • It is typically prescribed at a dose of 1 mg once daily, either as monotherapy in early Parkinson's disease or as an adjunct to levodopa therapy in more advanced stages.
  • The medication works by preventing the breakdown of dopamine in the brain, thereby prolonging its activity and improving motor symptoms.
  • Rasagiline has been shown to be effective in reducing "off" time and improving quality of life in patients with Parkinson's disease, as demonstrated in studies such as the ADAGIO and TEMPO trials 3.
  • Patients should be aware of potential interactions with certain foods and medications, and common side effects include headache, joint pain, and indigestion.

Benefits and Considerations

  • Rasagiline offers the convenience of once-daily dosing without the need for dietary restrictions at the standard therapeutic dose.
  • It is generally well tolerated, with a low incidence of cognitive and behavioral adverse events.
  • The medication has been shown to be cost-effective, making it a valuable option for patients with Parkinson's disease.
  • However, further studies are needed to fully establish the neuroprotective effects of rasagiline and to compare its efficacy with other medications used to treat Parkinson's disease 4.

Clinical Use

  • Rasagiline can be used as monotherapy in early Parkinson's disease or as adjunctive therapy to levodopa in more advanced stages.
  • The recommended dosage is 1 mg once daily, and it can be adjusted based on individual patient needs and response to treatment.
  • Patients should be monitored regularly for potential side effects and interactions, and adjustments to the treatment regimen should be made as needed.

References

Related Questions

What is the role of Rasagiline (monoamine oxidase B inhibitor) in the treatment of Parkinson's disease?
What are the treatment options for tremor-dominant Parkinson's disease in patients intolerant to NeuroPro (Rotigotine) 4 mg/24 hours, Rasagiline, Azilect (Rasagiline), and Sinemet (Carbidopa/Levodopa)?
What should be done if a dose of rasagiline (monoamine oxidase B inhibitor) is missed?
What are the abnormal physical exam findings of Parkinson's disease (PD) with toe tapping, specifically describing the characteristic changes in motor function?
What are alternative antidepressants to Selective Serotonin Reuptake Inhibitors (SSRIs) for patients on rasagiline (Monoamine Oxidase B (MAO-B) inhibitor)?
What should be done for a patient experiencing fatigue and shortness of breath (SOB) with electrocardiogram (ECG) changes showing marked mid and left precordial repolarization disturbance after taking a double dose of digoxin (digitalis glycoside)?
What are the VNI (Vulnerable Narcotics Intervention) criteria for medical evaluation and intervention?
What is Cardura (doxazosin)?
What is the recommended dose of amoxicillin (amoxicillin) for a 63kg pediatric patient with bronchitis?
What is the optimal treatment for a patient who has experienced a Transient Ischemic Attack (TIA) while on aspirin (acetylsalicylic acid) and statin (HMG-CoA reductase inhibitor)?
What is the normal size of a thyroid lobe?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question